drugset / Trial / NCT05076786
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
Phase 2
Unknown
28 enrolled
Peking Union Medical College Hospital
Harbin Medical University · collabThe First Affiliated Hospital of Xiamen University · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of chidamide combined with etoposide and cisplatin/carboplatin in the first-line treatment of advanced extrapulmonary neuroendocrine carcinoma.
Timeline
- Start
- 2021-10-27
- Primary completion
- 2022-10-15
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |